Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients

Rheumatology

Volumn 46, Issue 2, 2007, Pages 327-334

  Salliot, Carine ^a,b   Gossec, L ^a   Ruyssen Witrand, A ^a   Luc, M ^a   Duclos, M ^a   Guignard, S ^a   Dougados, M ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NONE   (France)

Author keywords

Blockers; Retrospective; Rheumatic diseases; Serious infections; TNF

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; BACTERIAL INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG FATALITY; FEMALE; GASTROINTESTINAL INFECTION; GENITAL TRACT INFECTION; HUMAN; INCIDENCE; INFECTION; INFECTION RATE; INFECTION RISK; INFECTIOUS ARTHRITIS; JOINT SURGERY; LUNG INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIOSIS; MYCOSIS; PARASITOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SEPTICEMIA; SKIN INFECTION; SPONDYLOARTHROPATHY; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; UNIVARIATE ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; SKIN DISEASES, INFECTIOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846657544     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel236     Document Type: Article

References (40)

1. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
2. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-602.
3. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
5. Moreland LW, Cohen SB, Baumgartner SW et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
6. Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
7. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
8. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 1997;337:1029-35.
9. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000;356:385-90.
10. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
11. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
12. Singh G, Ramey DR, Rausch PL, Schettler JD. Serious infections in rheumatoide arthritis: Relationship to immunosuppressive use. Arthritis Rheum 1999;42(Suppl.):S71-474.
13. Dixon WG, Hyrich KL, Watson K, Symmons DPM, Silman AJ and the BSR Biologics Register. Serious infection rates in patients receiving biologics therapy in the United Kingdom: Results from the BSR biologics register. EULAR congress 2005, OP0094.
14. Jacobsson LTH, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. No increase of severe infections in rheumatoid arthritis patients treated with TNF-blockers. EULAR congress 2005, SAT0164.
15. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003;42:617-21.
16. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
17. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9.
18. Keystone EC. Safety of biologic therapies-an update. J Rheumatol Suppl 2005;74:8-12.
19. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
20. Nestea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7.
21. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
22. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-[alpha] antagonists. Medicine 2005; 84:291-302.
23. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Amor B, Dougados M, Listrat V et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;62:10-5.
25. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. New Engl J Med 1988;318:1728-33.
26. Sierra F. Evidence-base medicine in practice: Applying number needed to treat and number needed to harm. Am J Gastroenterol 2005;100:1661-3.
27. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann intern Med 1997;126: 712-20.
28. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
29. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003;29:2327-9.
30. Haerter G, Manfras BJ, de Jong-Hesse Y et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004;39:e88-94.
31. Gardam MA, Keystone EC, Menzies R et al., Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
32. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(Suppl.):34-8.
33. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005;41 (Suppl.):S194-8.
34. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept? Clin Infect Dis 2005;41(Suppl.):S199-203.
35. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005;74:35-9.
36. Dinarello CA. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 2005;74:40-7.
37. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
38. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791.
39. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
40. Pincus T, Stein CM. Why randomised clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies; Clin Exp Rheumatol 1997;15(Suppl. 17):S27-38.